MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%

Sector Heatmap

Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%

KNSA — Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Nasdaq

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

CompareBack to Screener
$76.31
+0.52(+0.69%)
O
75.97
H
76.79
L
75.29
V
391.49K
⏱️ End-of-day dataAs of Oct 5, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Chart

About KNSA

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateMay 24, 2018
Employees366
Stock ExchangeNasdaq
Ticker SymbolKNSA
Websitehttps://www.kiniksa.com

Key Financial Statistics

Market Cap$5.91B
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$35.20 - $82.94
52-Week Avg Volume620.0K
VWAP$76.21
Transactions9,820
Total Recorded Bars2,101 days